Is dipeptidylpeptidase IV the missing link in angiotensin-converting enzyme inhibitor-induced angioedema?

Hypertension

Volumn 51, Issue 1, 2008, Pages 45-47

  Grouzmann, Eric ^a   Buclin, Thierry ^a  

^a University of Lausanne Medical Center   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

6 (3 AMINO 1 PIPERIDINYL) 1 (2 CYANOBENZYL) 3 METHYLURACIL; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV; ENALAPRIL; OMAPATRILAT; SAXAGLIPTIN; SITAGLIPTIN; VILDAGLIPTIN;

ANGIONEUROTIC EDEMA; DRUG SURVEILLANCE PROGRAM; EDITORIAL; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME INHIBITION; ENZYME METABOLISM; EX VIVO STUDY; FOOD AND DRUG ADMINISTRATION; GERIATRIC PATIENT; HUMAN; NASAL BIOPSY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RISK ASSESSMENT; SMOKING;

ANGIOEDEMA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIGENS, CD26; BRADYKININ; ENZYME INHIBITORS; HUMANS; HYPERTENSION; NEPRILYSIN; PEPTIDYL-DIPEPTIDASE A; SUBSTANCE P;

EID: 37349071751     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.107.101329     Document Type: Editorial

References (16)

1. Cameron HA, Higgins TJ. Clinical experience with lisinopril. Observations on safety and tolerability. J Hum Hypertens. 1989;3(suppl 1):177-186.
2. Skidgel RA, Erdös EG. Angiotensin converting enzyme (ACE) and neprilysin hydrolyze neuropeptides: a brief history, the beginning and follow-ups to early studies. Peptides. 2004;25:521-525.
3. Barnes PJ. Asthma as an axon reflex. Lancet. 1986;1:242-245.
4. Byrd JB, Adam A, Brown NJ. Angiotensin-converting enzyme inhibitor-associated angioedema. Immunol Allergy Clin North Am. 2006;26:725-737.
5. Grouzmann E, Monod M, Landis B, Wilk S, Brakch N, Nicoucar K, Giger R, Malis D, Szalay-Quinodoz I, Cavadas C, Morel DR, Lacroix JS. Loss of dipeptidylpeptidase IV activity in chronic rhinosinusitis contributes to the neurogenic inflammation induced by substance P in the nasal mucosa. FASEB J. 2002;16:1132-1134.
6. Byrd JB, Touzin K, Sile S, Gainer JV, Yu C, Nadeau J, Adam A, Brown NJ. Dipeptidyl peptidase IV in angiotensin-converting enzyme inhibitor-associated angioedema. Hypertension. 2008;51:141-147.
7. Kostis JB, Packer M, Black HR, Schmieder R, Henry D, Levy E. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens. 2004;17:103-111.
8. Pellacani A, Brunner HR, Nussberger J. Plasma kinins increase after angiotensin-converting enzyme inhibition in human subjects. Clin Sci (Lond). 1994;87:567-574.
9. Nussberger J, Cugno M, Cicardi M. Bradykinin-mediated angioedema. N Engl J Med. 2002;347:621-622.
10. National Insitutes of Health. Effectiveness of bradykinin receptor blocker at reducing swelling associated with angiotensin converting enzyme (ACE) inhibitor-associated angioedema. Available at: http://clinicaltrials.gov/ct/ show/NCT00517582. Accessed September 28, 2007.
11. Van Der Velden VH, Naber BA, Van Hal PT, Overbeek SE, Hoogsteden HC, Versnel MA. Peptidase activities in serum and bronchoalveolar lavage fluid from allergic asthmatics-comparison with healthy non-smokers and smokers and effects of inhaled glucocorticoids. Clin Exp Allergy. 1999;29:813-823.
12. Mannucci E, Pala L, Ciani S, Bardini G, Pezzatini A, Sposato I, Cremasco F, Ognibene A, Rotella CM. Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus. Diabetologia. 2005;48:1168-1172.
13. Nathan DM. Finding new treatments for diabetes-how many, how fast. how good? N Engl J Med. 2007;356:437-440.
14. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007;298:194-206.
15. Messerli FH, Nussberger J. Vasopeptidase inhibition and angio-oedema. Lancet. 2000;356:608-609.
16. European Medicines Agency. EPARS for authorised medicinal products for human use. Available at: http://www.emea.europa.eu/humandocs/Humans/EPAR/ januvia/januvia.htm. Accessed September 28, 2007.